S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer

Journal article

Abstract We have previously shown that expression of S100PBP, an S100P binding partner, gradually decreases during progression of pancreatic ductal adenocarcinomas (PDAC). Here, we show that loss of S100PBP leads to oncogenic transformation of pancreatic cells; after deregulation of S100PBP expression, both in silico and in vitro analyses highlighted alterations of genes known to modulate cytoskeleton, cell motility and survival. Overexpression of S100P reduced S100PBP expression, while co-immunoprecipitation indicated the interaction of S100P with S100PBP-p53-ubiquitin protein complex, likely causing S100PBP degradation. The doxycycline-induced Kras G12D activation resulted in decreased S100PBP levels, while low-dose treatment with HDAC inhibitor MS-275 rescued its expression in both human and mouse PDAC cell lines. This indicates Kras G12D as an upstream epigenetic regulator of S100PBP. Finally, analysis of TCGA PanCancer Atlas PDAC datasets demonstrated poor prognosis in patients with high S100P and low S100PBP expression, suggesting that S100PBP is a novel tumour suppressor gene with potential clinical utility.

Authors: Srivastava, K; Lines, KE; Jach, D; Crnogorac-Jurcevic, T

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer Nature [academic journals on nature.com]
• Journal: Oncogene
• Volume: 42
• Issue: 46
• Pages: 3422-3434
• Publication date: 2023-10-04
• DOI: 10.1038/s41388-023-02851-y
• EISSN: 1476-5594
• ISSN: 0950-9232
• Language: English
• Keywords: Mutation; Tumor suppressor gene; Internal medicine; Genetics; Suppressor; Carcinogenesis; Cancer; Cancer research; KRAS; Pancreatic cancer; Biology; Colorectal cancer; Molecular oncology; Gene